A substantially water-free ocular treatment composition including about 20% to about 45% beeswax and about 20% to about 45% jojoba oil. The composition can include at least one additional surfactant ingredient. The composition can be administered to a patient to improve the functionality of the tear film and decrease dry eye symptoms. The composition can be a semi-solid at room temperature and can liquefy when contacted with the skin at body temperature.

A substantially water-free ocular treatment composition including about 20% to about 45% beeswax and about 20% to about 45% jojoba oil. The composition can include at least one additional surfactant ingredient. The composition can be administered to a patient to improve the functionality of the tear film and decrease dry eye symptoms. The composition can be a semi-solid at room temperature and can liquefy when contacted with the skin at body temperature.

Disclosed is a powdered plant preparation and a method for its preparation, as well as microgranules and tablets obtained therefrom, and methods for their preparation. The invention is suitable for use in the production of herbal preparations.

Disclosed is a powdered plant preparation and a method for its preparation, as well as microgranules and tablets obtained therefrom, and methods for their preparation. The invention is suitable for use in the production of herbal preparations.

Systems and methods for extracting a compound of interest from plant material, such as acannabidiol (CBD) from cannabis, are provided. Particularly, the disclosed systems and methods utilize a crude oil to separate water, fats, and proteins prior to preparation of a CBD distillate. The systems and methods are operable with conventional solvents containing between about 5 wt % and about 8 wt % water.

A substantially water-free ocular treatment composition including about 20% to about 45% beeswax and about 20% to about 45% jojoba oil. The composition can include at least one additional surfactant ingredient. The composition can be administered to a patient to improve the functionality of the tear film and decrease dry eye symptoms. The composition can be a semi-solid at room temperature and can liquefy when contacted with the skin at body temperature.

A substantially water-free ocular treatment composition including about 20% to about 45% beeswax and about 20% to about 45% jojoba oil. The composition can include at least one additional surfactant ingredient. The composition can be administered to a patient to improve the functionality of the tear film and decrease dry eye symptoms. The composition can be a semi-solid at room temperature and can liquefy when contacted with the skin at body temperature.

A composition for prevention, alleviation, or treatment of respiratory diseases, and a functional food and a pharmaceutical composition, each comprising same. There is also provided a composition for the enhancement of respiratory functions and the alleviation of respiratory diseases, comprising an Impatiens arguta extract as an active ingredient.

A composition for prevention, alleviation, or treatment of respiratory diseases, and a functional food and a pharmaceutical composition, each comprising same. There is also provided a composition for the enhancement of respiratory functions and the alleviation of respiratory diseases, comprising an Impatiens arguta extract as an active ingredient.

The present invention provides novel compositions for suppressing or improving hair loss, and compositions for suppressing or improving graying. More specifically, it provides agents that stabilize type XVII collagen expression, preferably agents that suppress the degradation of type XVII collagen by ELANE inhibitors and such, and compositions comprising a DNA repair-promoting agent or a DNA damage-suppressing agent as an active ingredient. Advantageous suppressive effects of hair loss and graying can be obtained when a composition comprising as an active ingredient a suppressive agent of type XVII collagen degradation such as an ELANE inhibitor is administered to a mammal. For the ELANE inhibitors, suppressive agents of type XVII collagen degradation and DNA repair-promoting agents, low-molecular compounds, polypeptides, proteins, antibodies, or nucleic acid medicine such as antisense oligos or siRNAs may be used. A method of screening for effective substances for suppression of hair loss and graying is also provided.